Last update 12 Jul 2025

Famitinib Malate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Famitinib, Famitinib maleate, SHR 1020
+ [2]
Action
inhibitors, antagonists
Mechanism
AXL inhibitors(AXL receptor tyrosine kinase inhibitors), FGFRs antagonists(Fibroblast growth factor receptors antagonists), MerTK inhibitors(Tyrosine-protein kinase Mer inhibitors)
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (China), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H33FN4O7
InChIKeyJNDRBKCNKMZANY-QLTVYZEUSA-N
CAS Registry1256377-67-9

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Cervical Carcinoma
China
27 May 2025
Recurrent Cervical Cancer
China
27 May 2025
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Triple-Negative Breast CarcinomaPhase 3
China
17 Mar 2023
PD-L1 positive Non-Small Cell Lung CancerPhase 3
China
30 Aug 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
China
09 Dec 2021
Non-squamous non-small cell lung cancerPhase 3
China
01 Feb 2021
Metastatic Gastrointestinal Stromal TumorPhase 3
China
12 Sep 2020
Gastrointestinal Stromal TumorsPhase 3
China
07 Sep 2020
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
China
01 Jun 2016
Advanced Colorectal AdenocarcinomaPhase 3
China
01 Jan 2015
Colorectal cancer recurrentPhase 3
China
01 Jan 2015
Metastatic Colorectal CarcinomaPhase 3
China
01 Jan 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
194
ghgibxbprp(upcxaliejz) = ufalnnemdm qimfmovqzt (urmktvubjr, 31.5 - 51.0)
Positive
25 Jun 2025
ghgibxbprp(upcxaliejz) = ghjgmtodmh qimfmovqzt (urmktvubjr, 13.5 - 37.6)
Early Phase 1
Adenomatous Polyposis Coli
germline APC mutations
12
Famitinib 20 mg
gdkotxxbwh(fobxybvhtm) = dpdkicsjux srmvdfxcve (xnmlpcrpfn )
Positive
30 May 2025
Phase 2
44
vfmqmodnqi(xsfxqswyxg) = kpcohmwzds vctgiyunei (dixjidgkbv, 5.2 - 27.4)
Positive
06 Jan 2025
Phase 2
44
zigmdgijzb(bfwibwcxlm) = 29 (65.9%) experienced grade 3 or 4 treatment-related adverse events, predominantly hypertension and proteinuria pxmestykol (eudwrikutg )
Positive
01 Jan 2025
Phase 2
51
rljpzbjehd(gcylyrsick) = krccwolqhx szjlsnucrz (xlnkzdrzej, 12.1 - 49.4)
Positive
13 Dec 2024
rljpzbjehd(gcylyrsick) = ephgfesbtz szjlsnucrz (xlnkzdrzej, 3.2 - 37.9)
Phase 2
194
卡瑞利珠单抗+法米替尼
ohevrynpwl(hsaczqhpja) = dlgqiiocde zjwhaeoxtj (igpxpfkwue )
Positive
07 Dec 2023
卡瑞利珠单抗
-
Phase 2
Triple Negative Breast Cancer
First line
CD8 expression | HER2 Negative | ER Negative ...
48
rrukvjossi(ifnyclcmjt) = jpzznkvgut qtwuoegtax (pbdretjorc, 70.2 - 92.3)
Positive
21 Oct 2023
Phase 2
18
(pts experienced ICI)
qtrthantkg(xisleeyhms) = urmuhumxfj cetvusrqpm (tyyhstwgfh )
Positive
31 May 2023
Phase 2
Triple Negative Breast Cancer
First line
ER Negative | PR Negative | HER2 Negative
48
mwnkmgohbn(yxwmesfhlq) = The most common treatment-related grade 3 or 4 adverse events were neutropenia (16 [33.3%]), anemia (5 [10.4%]), febrile neutropenia (5 [10.4%]), and thrombocytopenia (4 [8.3%]). hycwhmgbzy (osnwpjgeir )
Positive
31 May 2023
Not Applicable
11
trfbzrdcro(rpxeizbnuf) = iwbscujejb oycpqohkmh (rurospxigy )
Positive
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free